To determine how vasopressin affects the vas cular tone of the smaller cerebral arterioles, we carried out an in vitro study of isolated and cannulated intrace rebral arterioles of rats. We found that increasing con centrations of vasopressin induced a triphasic response of vasodilation (10-1 2 _10-11 M), vasoconstriction (10-10-
10-8 M), and vasodilation stabilizing to control diameter (10-7-10-6 M) and that the maximum constriction was twice the maximum dilation in these smaller arterioles [21.2 ± 13.1% (mean ± SD) decrease in diameter vs. 11.2 ± 5.7% increase]. Pretreatment of the arterioles with� monomethyl-L-arginine (10-4 M), a specific inhibitor of endothelium-derived relaxing factor, abolished the vaso pressin-induced vasodilation and significantly increased the vasoconstriction. These results suggest that these ar terioles were maintained in a dilated state by an endothe-Vasopressin, a known circulating hormone and neuropeptide, has been implicated in the local con trol of cerebral blood flow, since vasopressin immunoreactive fibers and vasopressin receptors have been demonstrated in cerebral arteries (ltakura et aI. , 1988) and in cerebral microvessels (Pearlmutter et aI. , 1988) . However, the effects of vasopressin on the cerebral circulation are com plex. Vasopressin has been reported to be both a vasoconstrictor (Lluch et aI. , 1984; Nakai, 1987; Martin de Aguilera et aI. , 1990; Fugii et aI. , 1991) and a vasodilator (Kozniewska et aI. , 1979; Katusic lium-derived relaxing factor activated by vasopressin. Both vasodilation and vasoconstriction were found to be mediated through vasopressin VI receptors in a study of arterioles pretreated with d(CH 2 )5 Tyr(Me)arginine vaso pressin (10-6 M), a vasopressin VI receptor antagonist. These results support the hypothesis that vasopressin may constrict smaller cerebral arterioles while simulta neously dilating larger cerebral arteries. Our results also suggest that vasopressin may aggravate cerebral ischemia in pathological conditions, such as subarachnoid hemor rhage, when the arteriolar response to vasopressin shifts from vasodilation to vasoconstriction due to increased vasopressin levels in plasma and CSF and impaired en dothelium-derived relaxation. Key Words: Arterioles Cerebral microcirculation-Endothelium-derived relax ation-Vasopressin. et aI., 1984) . Perivascular application of high con centrations of lysine vasopressin failed to exert any influence on rat pial arterioles (Lassoff and Altura, 1980) . Our previous work showed that vasopressin dilated larger cerebral arteries, such as the basilar arteries, while decreasing vertebral blood flow (Su zuki et aI. , 1992) . We hypothesized that this dis crepancy could be explained by regional differences in responsiveness to vasopressin, i. e. , that vaso pressin tended to constrict small cerebral arterioles while it dilated larger cerebral arteries.
Three different actions have been proposed for vasopressin in the regulation of vascular smooth muscle tone. Of the two types of vasopressin recep tors (VI and V2) (Michell et aI. , 1979) , VI receptors mediate both vasoconstriction and vasodilation. Vasoconstriction has been shown to result from di rect effects of V 1 receptors of vascular smooth muscle in promoting calcium mobilization and ino sitol phosphate turnover (Doyle and Ruegg, 1985) and in inhibiting adenylate cyclase (Nambi et aI., 1986) . Vasodilation has been shown to result from the effects of VI receptors of the endothelium in promoting the release of endothelium-derived relax ing factor (EDRF) (Katusic et aI., 1984; Onoue et aI., 1988) . Vasopressin V2 receptors mediate a third mechanism of vasodilation, by activating adenylate cyclase and increasing cyclic AMP levels in vascu lar smooth muscle (AI-Omar Azzawi and Shirrley, 1983; Liard, 1989; Kozniewska and Szczepanska Sadowska, 1990) . The relative importance of these three mechanisms may differ between the larger ce rebral arteries and the smaller cerebral arterioles. In particular, the vasoconstrictor mechanism may pre dominate in the smaller cerebral arterioles.
To determine how vasopressin affects the vascu lar tone of smaller cerebral arterioles, we designed an in vitro study of isolated and cannulated cerebral arterioles from rats. Vasopressin in increasing con centrations was applied extraluminally to the arte rioles to investigate the dose-dependent response of smaller cerebral arterioles to vasopressin. Vaso pressin was then applied to arterioles pretreated with either an EDRF synthesis inhibitor or a VI antagonist to clarify the roles of EDRF and VI re ceptors in the effects of vasopressin on the vascular tone of smaller cerebral arterioles.
MATERIALS AND METHODS

Preparation of arterioles
Animal experimentation was conducted in conformity with the American Physiological Society's' 'Guiding Prin ciples in the Care and Use of Animals." Intracerebral arterioles were isolated and cannulated in an organ bath (composed as described below), and changes in vessel diameter in response to the extraluminal administration of agents were measured, as previously described in detail (Duling et aI., 1981; Dacey and Duling, 1982a; Takayasu and Dacey, 1989) . Briefly, penetrating intracerebral arte rioles, 40-80 j.Lm in diameter, were isolated surgically at 4°C from the first (M-l) portion of the middle cerebral arteries from the brains of pentobarbital-anesthetized male Sprague-Dawley rats weighing 300-400 g. Vessels were transferred to a temperature-controlled chamber on the stage of a Nikon inverted microscope and were can nulated at 25°C with glass pipettes. The inner diameter of the vessel was determined using a Video-dimension ana lyzer (Hamamatsu Photonics model C3160, Hamamatsu, Japan). After cannulation, transmural pressure was set and maintained throughout the experimental protocol at 60 mm Hg via the cannulating pipette. Bath temperature was brought to 37.5°C, and vessels were allowed to equil ibrate for 45 min at an extraluminal bath pH of 7.3. The bath was exchanged every 5 min. During the equilibration period of 30 min, vessels developed spontaneous tone, contracting to -70% of their maximum passive diameter. Vessel responsiveness was then assessed by changing ex traluminal pH from 7.3 to 6.8 and from 7.3 to 7.6. Vessels with poor spontaneous tone «20% decrease of diameter) or poor pH response « 12% change of diameter after pH changes) were discarded at this stage.
The physiologic salt solution used in this preparation was a modified Ringer's, composed of 144 mM NaCl, 3.0 mM KCl, 2.5 mM CaCI 2 , 1.4 mM MgS0 4 , 5.0 mM glu cose, 2.0 mM pyruvate, 0.02 mM ethylenediaminetetra acetic acid, 1.21 mM NaH 2 P0 4 , and 0.9-1.0 g/100 ml bo vine serum albumin. The extraluminal solution contained no albumin in our experimental setup, since CSF nor mally contains hundreds of times less albumin (-0.02 g/100 ml) than plasma (-4 g/100 ml) (Dacey and Duling, 1982a) . The pH of the solutions was maintained at 7.3 except when vessel responsiveness was assessed by pH change. The pH was adjusted by adding either HCl or NaOH.
Synthetic vasopressin (arginine vasopressin; A VP) was obtained from Peptide Institute (Osaka, Japan), EDRF synthesis inhibitor [NG-monomethyl-L-arginine; (L NMMA)] from Calbiochem (La Jolla, CA, U.S.A.), and synthetic vasopressin VI receptor antagonist [d(CH 2 h Tyr(Me)A VP] from Peninsula Laboratories (San Carlos, CA, U.S.A.). All other chemicals were of reagent grade.
All the agents were dissolved in physiologic salt solu tion and extraluminally applied to the arterioles after pH adjustment to 7.3.
Protocol
The experiments were organized into three series. In the first series, increasing concentrations 00-1 4 _10-6 M) of A VP were sequentially applied to six arterioles to de termine the dose-response curve of vasopressin in con trol vessels. In the second series, increasing concentra tions of the EDRF synthesis inhibitor L-NMMA were first applied to five arterioles to determine the minimum dose that produced the maximum effect on vessel diameter. Then, AVP 00-13_10-6 M) was applied to five arterioles after pretreatment with L-NMMA at that determined dose to investigate the role of EDRF in vasopressin effects on the arterioles. In the third series, increasing concentra tions of the vasopressin VI receptor antagonist [d(CH2k Tyr(Me)AVP] were applied to five arterioles to determine the best pretreatment dose as in the first series. Vaso pressin 00-13-10-6 M) was then applied to five arteri oles after V 1 antagonist pretreatment at the determined dose to investigate the role of VI receptors in vasopressin effects on the arterioles.
Statistical analysis
Vessel diameters at each agonist dose in the dose response sequence are expressed as a percentage of con trol vessel diameter. The magnitude of vasoconstriction and vasodilation is expressed as percentage change of diameter from the control vessel diameter. These data are reported as means ± SD. Significance of differences in the mean diameter at each agonist dose was evaluated by one-way analysis of variance. When we found significant differences between mean diameters at given doses, we performed the Fisher Protected Least Significant Differ ence (PLSD) multiple range test. The significance of dif ferences in vessel diameter in the magnitude of vasocon striction or vasodilation at a given dose of A VP between unpretreated control and pretreated arterioles was eval uated by unpaired t test. The analysis-of-variance test was also applied, before application of drugs, to evalulate differences in baseline vessel characteristics such as ves sel diameter and pH response to pH 6.8 and 7.6 between arterioles used in each series of experiments. We consid ered differences significant at p < 0.05.
RESULTS
Cerebral arterioles from six rats with an average diameter of 64. 1 ± 13. 7 (mean ± SD) f1m showed a triphasic response to increasing concentrations (10-14 _10-6 M) of vasopressin, in which constric tion was two times greater than dilation (Fig. 1) . The arterioles dilated at lower doses (10-12 -10 -11 M), with a significant dilation of 11. 2 ± 5. 7% at 10-11 M. At higher doses 00-10 -10-8 M), the ar terioles contracted significantly, with a maximum contraction of 21. 2 ± 13. 1% at 10-8 M. As A VP doses increased> 10-8 M, the arterioles gradually dilated, stabilizing at 99. 0 ± 7. 2% of control.
Administration of L-NMMA contracted five arte rioles in a dose-dependent manner with an EC5 0 of 3 x 10-6 M and a maximum contraction of 14. 2 ± 2. 7% at 10-4 M, which concentration was then used for pretreatment. The dose was compatible with those reported in the literature (Sakuma et aI. , 1988; Rees et aI. , 1989) . Pretreatment with L-NMMA (10-4 M) abolished vasopressin-induced vasodila tion and increased its vasoconstriction (Fig. 2) . Above 10-11 M A VP, the dose-response curve of arterioles pretreated with L-NMMA showed a pat tern of vasoconstriction parallel to, but �20% greater than, that of control vessels. Above 10-8 M A VP, the arterioles gradually dilated and stabilized at 78. 9 ± 12. 1% at 10-6 M similarly to control ar terioles. The maximum contraction in L-NMMA pretreated arterioles was twice that in unpretreated controls (39. 2 ± 7. 8 vs. 21. 2 ± 13. 1% at 10-8 M AVP). Differences of arteriolar diameter in vaso pressin dose-response curves without and with L-NMMA pretreatment were statistically significant at concentrations of vasopressin between 10-12 and 10-6 M ( Table 1) . Administration of a vasopressin VI receptor an tagonist dilated five arterioles in a dose-dependent manner with an EC5 0 of 6 x 10 -12 M and a maxi mum dilation of 6. 6 ± 1. 1% at 10 -6 M, which was used for pretreatment. The dose was compatible with those reported in the literature (Kruszynski et aI. , 1980; Katusic et aI. , 1984) . Pretreatment of five arterioles with the VI antagonist blocked both va sopressin-induced vasodilation and vasoconstric tion, with no significant differences in mean vessel diameters over the vasopressin dose-response curve (p = 0. 29) (Fig. 2) . Differences of arteriolar diameter in vasopressin dose-response curves with out and with VI antagonist pretreatment were sig nificant at concentrations of vasopressin between 10-12 and 10-10 M and at 10-8 M ( Table 1) .
The arterioles used for each series of the experi ments had similar baseline characteristics in control vessel diameter and response to pH 6.8 and 7.6 be fore application of drugs, suggesting that the differ ences in response to vasopressin in each group of arterioles were not due to differences in arteriolar characteristics (Table 2) .
DISCUSSION
This study demonstrated that increasing concen trations of vasopressin induced a triphasic response of vasodilation, vasoconstriction and vasodilation, stabilizing to control diameter in smaller arterioles of the cerebral microcirculation of rats. In addition, the constrictor response by vasopressin was more pronounced than the dilator response in these arte rioles. This may also be true in in vivo cerebral arterioles, since it has been shown that our isolated intracerebral arterioles have stable spontaneous tone and reactivity throughout the experiments, which are compatible with those developed by other vascular smooth muscle preparations (Dacey and Duling, 1982b) . The degree of vasodilation by intrinsic vasodilators such as adenosine is similar between our isolated intracerebral arterioles in vitro and pial arterioles in cranial window preparations in vivo (Dacey and Duling, 1982a; Morii et aI., 1986) . These results support the hypothesis that vaso pressin constricts smaller arterioles while dilating larger cerebral arteries, a hypothesis made to ex plain our previous discordant findings that intraar terially administered vasopressin markedly dilated larger cerebral arteries such as the basilar artery while simultaneously decreasing vertebral blood flow in dogs (Suzuki et aI. , 1992) . Regional differences in vasopressin responsive ness of the cerebral vasculature have also been shown by other investigators (Faraci et aI., 1988) . Their in vivo study using cats demonstrated that intravenous vasopressin increased the resistance of small pial arteries, while it decreased the resistance of larger pial arteries, suggesting a predominantly constrictor response to vasopressin in smaller cere bral arteries. However, they ascribed the increase in small arterial resistance after vasopressin treat ment to an autoregulatory response to the increase in intraarterial pressure due to the decreased resis tance of large arteries, rather than to the direct va soconstrictor effects of vasopressin demonstrated in the present study.
The study using L-NMMA, a specific inhibitor of EDRF or NO (Sakuma et aI. , 1988; Palmer and Moncada, 1989; Rees et aI. , 1989) , suggested that endothelium-derived relaxation played a role in va sodilation induced by vasopressin in the cerebral arterioles. In control arterioles the threshold dose of AVP for dilation (10-12 M) was much lower than that for constriction (10-9 M). Maximum vasodila tion was produced at 10 -11 M, maximum vasocon striction at 10-8 M. The vasopressin dose-response curve of L-NMMA-pretreated arterioles was shifted toward constriction, parallel to the control dose response curve, by �20% of vessel diameter from 10-11 to 10 -6 M A VP, suggesting that the maximal dilating effects of endothelium-derived relaxation are maintained at these concentrations of AVP. Va sodilation (or decrease of vasoconstriction) in the third phase of the dose-response curve to vaso pressin 00-7 _10-6 M) was maintained in arterioles pretreated with L-NMMA, suggesting that this phase of vasodilation was not mediated by EDRF. Dose-dependent contraction of control arterioles by L-NMMA might suggest that there was basal re lease of EDRF in cerebral arterioles that maintained a slightly dilated arteriolar tone.
This study indicated that both the vasoconstric tion and the vasodilation caused by vasopressin in cerebral arterioles were mediated through vaso- Values are those before application of drugs. Data are means ± SD. IL-NMMA, pretreatment with ,vG-monomethyl-L-arginine; /VIA, pre treatment with VI antagonist; AN OVA, analysis of variance.
pressin VI receptors, since the specific VI receptor antagonist blocked both actions of vasopressin. The VI antagonist d(CH 2 hTyr(Me)AVP is one of the most potent and selective VI antagonists and the most widely used (Kruszynski et aI. , 1980; Thibon nier, 1990; Laszlo et aI. , 1991) . These findings are in agreement with those of previous reports (Katusic et aI. , 1984; Martin de Aguilera et aI. , 1990) . The intracarotid administration of a V2 agonist in rats was reported to increase cerebral blood flow and cerebral oxygen consumption and to decrease cerebral vascular resistance (Kozniewska and Szczepanska-Sadowska, 1990) , possibly due to an indirect vasodilative influence of vasopressin by an increase in the metabolism of vasopressin-sensitive neuronal systems (Landgraf et aI. , 1978) . Our re sults suggest that V2 receptors are unlikely to play a major role in the direct regulation of cerebral ar teriolar tone since pretreatment of the arterioles with the VI receptor antagonist abolished both va sodilation and vasoconstriction.
In this study, vasoconstriction decreased gradu ally when vasopressin concentrations increased above 10-8 M. This phase of the vasodilation dis appeared in arterioles pretreated with a V 1 antago nist, suggesting that it may be mediated by VI re ceptors but not by V2 receptors. Decreased effects of vasopressin at higher concentrations have also been shown in other studies (Katusic et aI. , 1984; Onoue et aI. , 1988; Martin de Aguilera et aI. , 1990 ), but the underlying mechanism has not yet been elu cidated. One possible mechanism in our study may have been tachyphylaxis due to repeated, cumula tive administrations of vasopressin. Tachyphylaxis with vasopressin has been demonstrated during ce rebral blood flow measurement in cats (Kozniewska et aI. , 1979) and with isometric tension measure ment in isolated human cerebral arteries (White and Robertson, 1987) . Lassoff and Altura (1980) re ported that perivascular application of lysine vaso pressin failed to exert any influence on the rat pial terminal arterioles. The doses used in their study were 5 x 10-7 -1 X 10-2 M (1 x 10-4 -2. 0 IU/O.l mI), when the concentrations were converted to molarity from international units. Even the lowest dose used in their study was that for the third phase of our dose-response curve, in which the arterioles dilated, stabilizing to the control diameter. Their doses might have been too high to exert any influ ence on rat pial arterioles. These results may indi cate that higher doses of vasopressin probably have no effects on cerebral arteriolar tone by unknown mechanisms other than tachyphylaxis.
Vasopressin may play a role in the pathogenesis of cerebral ischemia. As we report here, physio-J Cereb Blood Flow Metab, Vol. 13, No.2, 1993 logic concentrations of vasopressin (-10 -II M in plasma and 10-12 Mi n CSF) (Cameron et al. , 1984) induce mild vasodilation in cerebral arterioles. However, during certain pathological conditions, including hemorrhagic shock, intracranial hyperten sion, severe hypoxia, and subarachnoid hemor rhage (SAH), vasopressin levels in both plasma and CSF increase up to 300-fold (Rap and Chwalbinska Moneta, 1978; Mather et aI. , 1981; Wang et aI. , 1981; Cameron et aI. , 1984) . Such concentrations of vasopressin are high enough to induce constriction of cerebral arterioles, as shown in this study, and may aggravate cerebral ischemia.
In patients with SAH, vasopressin may play an even more important role in the development of ce rebral ischemia. In addition to an increase in vaso pressin levels, it is widely accepted that endothe lium-derived relaxation is impaired after SAH (Na kagomi et aI. , 1987; Kim et aI. , 1988; Suzuki et aI. , 1992) . In conditions of impaired endothelium derived relaxation, even physiologic concentrations (-10 -II M) of vasopressin may induce constriction of cerebral arterioles, as shown by the dose response curve in the arterioles pretreated with L-NMMA in our study. Furthermore, the higher concentrations of vasopressin in plasma than in CSF may penetrate the blood-brain barrier and gain access to vascular smooth muscle cells more easily after SAH, since the blood-brain barrier is often disrupted in pathological conditions such as SAH (Sasaki et aI. , 1985; Johshita et al. , 1990) . Increased levels of vasopressin together with impaired endo thelium-derived relaxation and a porous blood brain barrier may thus combine to induce contrac tion of the arterioles in the cerebral microcircula tion and to aggravate cerebral ischemia.
In conclusion, we have shown that vasopressin in increasing concentrations induces a triphasic re sponse of vasodilation, vasoconstriction, and va sodilation, stabilizing to control diameter in cere bral arterioles of rats. We have also shown that vasopressin-induced vasoconstriction is more prominent than vasodilation in these arterioles. These results support our hypothesis that vaso pressin may constrict smaller cerebral arterioles while simultaneously dilating larger cerebral arter ies. Our results also suggest that vasopressin may play an important role in the pathogenesis of cere bral ischemia in certain pathological conditions such as SAH. In such conditions, the arteriolar re sponse to vasopressin may be shifted from vasodi lation to vasoconstriction due to increased vaso pressin levels in plasma and CSF and impaired endothelium-derived relaxation and thus may ag gravate cerebral ischemia.
